Cost-effectiveness analysis of rezivertinib and gefitinib in patients with EGFR-mutated advanced non-small cell lung cancer
1. 当前求助状态已完结, 请及时下载应助文件
2. 系统将在 2026-08-24 16:11:03 删除文件
注: 所有应助的资源仅供学习交流使用, 不得违反相关法律法规
DOI: 10.1080/14737167.2026.2626573
文献链接: https://www.tandfonline.com/doi/full/10.1080/14737167.2026.2626573
其他信息:
出版社: Informa UK Limited
作者: Conghui Kou; Huina Wu; Lihui Liu; Xifeng Zhao; Jing Nie

